Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Savient Pharmaceuticals Inc    SVNT

SummaryNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

Savient to Reduce Work Force in Restructuring

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 06:35pm CET

Savient Pharmaceuticals Inc. (>> Savient Pharmaceuticals, Inc.) unveiled plans to reduce the size of its work force by more than a third as it aims to reduce its operating costs, and the specialty biopharmaceutical company also named the head of its North American commercial business as its new president and chief executive.

Shares were up 4.2% at 64 cents in recent trading. The stock has fallen about 71% this year.

The company selected Louis Ferrari, who joined Savient in February 2011, to succeed John H. Johnson, who left the company earlier this year to become chief executive at Dendreon Corp. (>> Dendreon Corporation). He takes the reigns from David Norton, who has headed Savient on an interim basis since Mr. Johnson's departure.

Savient Chairman Stephen Jaeger said that since joining Savient, Mr. Ferrari has played a key role in the continuing rollout of Krystexxa treatment for gout and development of the company's growth strategies.

The work-force reduction, which includes current vacancies, will include a restructuring of its field force to 35 key account managers and three regional business directors. Savient aims to generate annual operating cost savings of about $56 million by 2013, including roughly $6.5 million of operating expense savings in 2012.

About $4.7 million in restructuring and employee severance charges are anticipated, including $3.6 million during 2012.

Prior to joining Savient, Mr. Ferrari had a long career of increasing responsibility at health-care giant Johnson and Johnson (>> Johnson & Johnson), where he most recently served as vice president of oncology and nephrology.

Write to Tess Stynes at Tess.Stynes@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SAVIENT PHARMACEUTICALS IN
2013 SAVIENT PHARMACEUTICALS INC : Savient Receives Approval From Bankruptcy Court To..
2013 SAVIENT PHARMACEUTICALS INC : Savient Reaches Agreement On Use Of Cash Collatera..
2013DJD. E. SHAW & CO. LP 3Q 13F : Largest Eliminations -2-
2013DJD. E. SHAW & CO. LP 3Q 13F : Largest Eliminations
2013 SAVIENT PHARMACEUTICALS INC : Savient Receives Court Approval Of Key "First Day"..
2013 SAVIENT PHARMACEUTICALS INC : SVNT, CZR, MTSL and FUEL added to NASDAQ Active St..
2013DJU.S. HOT STOCKS FUTURES : Hot Stocks to Watch
2013 SAVIENT PHARMACEUTICALS INC : Savient Pharmaceuticals files for Chapter 11 bankr..
2013 SAVIENT PHARMACEUTICALS INC : Savient Pharmaceuticals Commences Voluntary Chapte..
2013 SAVIENT PHARMACEUTICALS INC : Savient Announces Multiple Abstracts Related to KR..
More news
Sector news : Biotechnology & Medical Research - NEC
01:25aDJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Income Statement Evolution
More Financials
Sector and Competitors
1st jan.Capitalization (M$)
SAVIENT PHARMACEUTICAL..0
INCYTE CORPORATION-5.68%19 219
QUINTILES IMS HOLDINGS..11.90%18 225
CELLTRION, INC.--.--%9 953
SEATTLE GENETICS, INC.44.41%9 442
LONZA GROUP AG11.34%9 247
More Results